It is expected to treat squamous cell carcinoma of the head and neck. The anti-PD-1 antibody of mosadon has won the positive evaluation of the European Drug Commission

MSD today announced that the European Drug Administration's Committee on human medicinal products (CHMP) recommended approval of two options of keytruda (anti PD-1 therapy of MSD) for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) For patients with tumor expression of PD-L1 (with positive score [CPS] ≥ 1), keytruda is recommended as a single therapy or combined with platinum and 5-fluorouracil (5-FU) chemotherapy This recommendation is based on key phase 3 keynote-048 trial data, in which keytruda as a combination of monotherapy and chemotherapy compared to standard therapy (cetuximab plus carboplatin or cisplatin plus 5-FU) showed a significant improvement in overall survival in the corresponding patient population MSD currently has the largest clinical development program for head and neck squamous cell carcinoma, and is continuing to promote a variety of registered support studies Keytruda is planned to be studied as a monotherapy and in combination with other cancer therapies, including keynote-412 and keynote-689 The CHMP proposal will now be reviewed by the European Commission to obtain marketing permission from the EU The final decision will be made in the fourth quarter of 2019 (Bio Valley / bio on Com) original source: moshadong official website